Myomectomy Market: Market Size & Forecast 2026

The myomectomy market comprises surgical interventions, devices, and consumables used to excise uterine leiomyomas without removing the uterus, making it a critical option for women of reproductive age who wish to preserve fertility. Market sizing varies by source, with 2025-2026 estimates ranging roughly between $1.5 billion and $2.1 billion, reflecting differences in scope definitions, some reports covering the broader fibroid treatment ecosystem and others focused specifically on myomectomy procedures and equipment. A commonly cited baseline places the 2026 market near $1.8 billion, with forward projections reaching between $3.8 billion and $4.2 billion by 2034-2035, implying long-term CAGRs in the 8 to 9 percent range.

• •Market valued at approximately $1.8 billion in 2026, with forward projections of $3.8-$4.2 billion by 2034-2035 at CAGRs of 8-9%
• •Myomectomy is a fertility-sparing surgical alternative to hysterectomy for symptomatic uterine fibroid treatment
• •The segment sits within the broader women's health market ($44B+ in 2025) and the $7 billion uterine fibroids treatment devices market

Several interconnected factors are propelling market expansion. Rising global prevalence of uterine fibroids, affecting a significant proportion of women of reproductive age, combined with increased screening and diagnostic awareness is expanding the addressable patient population. Growing preference for fertility-sparing surgical options, particularly as women increasingly defer childbearing, is shifting demand toward myomectomy over more radical interventions.

• •High and well-documented prevalence of uterine fibroids in women of reproductive age drives a large and persistent addressable patient base
• •Rising awareness of fertility-sparing treatment options and delayed childbearing trends support demand for myomectomy over hysterectomy
• •Adoption of minimally invasive techniques, including laparoscopic and robotic-assisted approaches, reduces recovery times and expands procedural uptake

The market is broadly segmented by surgical approach, open abdominal, laparoscopic, hysteroscopic, and robotic-assisted, with minimally invasive techniques capturing an increasing share as technology and surgeon proficiency improve. By patient indication, procedures are classified across various fibroid types and locations, with submucosal and intramural fibroids representing the most common myomectomy targets.

• •North America holds the largest market share, supported by advanced clinical infrastructure and established reimbursement frameworks
• •Asia-Pacific is the fastest-growing region, driven by rising healthcare access, large demographic patient bases, and growing adoption of minimally invasive techniques
• •Segmentation spans surgical approach (open, laparoscopic, robotic), fibroid type and location, care setting, and end-user (public versus private healthcare)

Who are the notable companies in the industry?

The competitive landscape of the global myomectomy market is led by five major medical device innovators: Medtronic PLC, which offers advanced energy-based surgical systems and laparoscopic instruments for minimally invasive myomectomies; Intuitive Surgical Inc., a dominant force in robotic-assisted surgery through its da Vinci platform, enabling precise, tissue-sparing myomectomy procedures; Johnson & Johnson, leveraging its Ethicon division to provide a broad portfolio of surgical sutures, morcellators, and laparoscopic tools tailored for gynecological interventions; Stryker Corporation, contributing with high-performance endoscopic and electrosurgical systems designed for minimally invasive gynecologic surgery; and Karl Storz SE & Co. KG, a specialist in high-definition laparoscopic visualization and precision instrumentation critical for uterine fibroid removal. These firms collectively shape market dynamics through R&D investment, strategic product launches, and global distribution networks, while maintaining distinct technological niches, ranging from robotics to endoscopic imaging. Though the market remains moderately fragmented with regional suppliers competing on consumables, these five players exert outsized influence through integrated platforms that combine devices, disposables, and imaging, reinforcing their leadership across key procedural segments.

• •The market features a mix of large diversified manufacturers and specialized surgical technology producers, yielding moderate supply-chain consolidation
• •Producers operate either through integrated portfolios spanning multiple surgical device categories or as focused specialists in specific procedural technologies
• •Manufacturing and technology development capacity is concentrated in North America, Western Europe, and key Asia-Pacific hubs

What are the recent trends and outlook?

The market outlook through the early 2030s is shaped by continued innovation in minimally invasive surgical platforms, including advances in robotic-assisted and image-guided techniques that improve precision and reduce operative morbidity. Growing integration of digital surgical planning tools and enhanced intraoperative imaging is expected to further refine procedural outcomes and support market expansion. The market is also positioned to benefit from broader macro trends in women's health, including increased investment in gynecological conditions, rising patient advocacy, and a growing pipeline of less invasive treatment modalities.

• •Continued innovation in robotic-assisted and image-guided minimally invasive platforms is expected to sustain procedural adoption and market growth
• •Expanding clinical evidence and favorable reimbursement decisions will be key determinants of long-term adoption trajectories
• •Broader investment in women's health and rising awareness of fibroid-related conditions are likely to expand the addressable patient population over the forecast horizon